Lescarden Enters Into Distribution Agreement for Catrix(R) Wound Dressing in Taiwan
08 Julho 2010 - 10:30AM
Lescarden Inc. (OTCBB:LCAR) announced today that it had entered
into an agreement with Harvest Biotech Co., Ltd., Taipei City ,
Taiwan ROC granting Harvest Biotech a 10 year exclusive license to
market Lescarden's proprietary product, Catrix® Wound Dressing
and Catrix Skin Care in Taiwan.
Regulatory marketing approvals and product reimbursement
arrangements are being secured, and it is anticipated that
marketing approval and product introduction will commence in the
fourth quarter of 2010.
Catrix® Wound Dressing is a specially processed bovine cartilage
product in the form of a fine, white powder. The Wound Dressing is
approved by the FDA for the management of chronic skin wounds
including decubitus ulcers, venous stasis ulcers and diabetic
ulcers as well as second degree burns and post-radiation
dermatitis. Clinical studies conducted with Catrix® on patients
suffering from bed sores have demonstrated its ability to assist
patients who had previously been unresponsive to standard wound
care treatments. The same studies demonstrated the potential for
significant cost savings for both patient and caregiver in the
treatment of such non-healing lesions.
Harvest Biotech Co., Ltd. Is a newly incorporated company, fully
owned by Harvest and Health, a Taiwanese firm belonging to the
Juiti Group.
The Juiti Group is a leading supplier of pharmaceutical and
medical device products in the Taiwanese market with sales
exceeding US$ 92 million in 2008. Juiti's products range from renal
care to infusion therapy, emergency medicine, oncology, nephrology,
etc.
The Juiti Group distributes products of prestigious companies
including GSK, Astra Zeneca, Baxter, GE, Medtronic; it is staffed
with more than 130 employees and, besides its headquarters in
Taipei, it has branch offices in Taichung and Kaohsiung.
For Lescarden this agreement extends their penetration into the
Asian market for both Catrix® based clinical skin care and wound
care products. The Catrix® skin care line was introduced into
the Philippines at the annual meeting of the Philippine
Dermatologic Society in November 2007. In Korea, Catrix® based skin
care products are dispensed by over 400 dermatologists and medical
spas that specialize in clinical and aesthetic skin care
procedures. Daewoong Pharma Co. Ltd., the licensed distributor for
Catrix® Wound Dressing, is completing product studies necessary to
gain marketing approval in Korea.
Lescarden, Inc. is a biotechnology company dedicated to the
development of natural, biologic therapies for the chronic wound
care, dermatology and osteoarthritis markets. For more information
please contact the Company at 212-687-1050 or visit
www.catrix.com.
CONTACT: Lescarden Inc.
212-687-1050
www.catrix.com
Lescarden (CE) (USOTC:LCAR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Lescarden (CE) (USOTC:LCAR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024